Genmab A/S
Close on Nov 20, 2026
Genmab A/S Clinical Stage R&D Expense by Year
Clinical Stage R&D Expense (Annual Functional Split) ($M)
Genmab A/S Clinical Stage R&D Expense: $607M in FY2025, up 27.0% from a year earlier.
Where the FY2025 figure comes from
“|| Clinical³ | 607 | 478 | 476 | 27 % | — %”
Source: Genmab Statutory Annual Report 2025 (Consolidated, ESRS & Parent Company FS, Form 20-F Ex.) ↗
Consolidated R&D expense disaggregated by stage in Form 20-F Item 5 (Clinical, Development & CMC, Discovery Research, and Other).
annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Clinical Stage R&D Expense (Annual Functional Split) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 607 | +27.0% | Genmab Statutory Annual Report 2025 (Consolidated, ESRS & Parent Company FS, Form 20-F Ex.) ↗ |
| FY2024 | Dec 31, 2024 | 478 | +0.4% | Genmab Statutory Annual Report 2025 (Consolidated, ESRS & Parent Company FS, Form 20-F Ex.) ↗ |
| FY2023 | Dec 31, 2023 | 476 | – | Genmab Statutory Annual Report 2025 (Consolidated, ESRS & Parent Company FS, Form 20-F Ex.) ↗ |
Breakdown
What makes up clinical Stage R&D Expense
Cite this data
StockData. (2026). Genmab A/S Clinical Stage R&D Expense ($M), annual FY2023–FY2025 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/rd-func-clinical
See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.
See a number that looks wrong?